Home » Stocks » MTNB

Matinas BioPharma Holdings, Inc. (MTNB)

Stock Price: $0.791 USD -0.013 (-1.67%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $0.800 +0.009 (1.19%) May 7, 7:55 PM
Market Cap 161.50M
Revenue (ttm) 158,333
Net Income (ttm) -23.24M
Shares Out 196.89M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $0.791
Previous Close $0.804
Change ($) -0.013
Change (%) -1.67%
Day's Open 0.800
Day's Range 0.780 - 0.829
Day's Volume 1,216,788
52-Week Range 0.660 - 2.220

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BEDMINSTER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate ...

1 week ago - GlobeNewsWire

BEDMINSTER, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of cri...

1 week ago - GlobeNewsWire

BEDMINSTER, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Co...

4 weeks ago - GlobeNewsWire

– Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics –

1 month ago - GlobeNewsWire

BEDMINSTER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Co...

2 months ago - GlobeNewsWire

The company reported disappointing clinical results.

3 months ago - The Motley Fool

– LYPDISO ™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa ® –

3 months ago - GlobeNewsWire

Matinas has an OM3 drug that has demonstrated a superior profile to Amarin's Vascepa. It has a platform and, unlike Amarin, a diverse pipeline.

4 months ago - Seeking Alpha

The proposed brand name for its leading pipeline drug got an important nod.

4 months ago - The Motley Fool

BEDMINSTER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to a...

5 months ago - GlobeNewsWire

- Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022 -

5 months ago - GlobeNewsWire

– Dr. Liu brings more than 20 years of expertise in pharmaceutical development, formulation, and CMC, with specific focus on lipid-based delivery of complex molecules – – Dr. Liu brings more than 20 yea...

5 months ago - GlobeNewsWire

Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

BEDMINSTER, N.J., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to a...

5 months ago - GlobeNewsWire

BEDMINSTER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to a...

5 months ago - GlobeNewsWire

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

EnACT study of MAT2203 in cryptococcal meningitis received unanimous D ata and Safety Monitoring Board (DSMB) recommendation to pro ceed into second patient cohort

6 months ago - GlobeNewsWire

BEDMINSTER, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conferenc...

6 months ago - GlobeNewsWire

– DSMB evaluated both safety and efficacy data in recommending cohort progression –

6 months ago - GlobeNewsWire

If you're itching for a little excitement in your investing, these cheap stocks under $1 might be just what you're looking for. The post 7 Cheap Stocks Under $1 That Deserve A Second Look appeared first...

Other stocks mentioned: AMPE, GPL, GPOR, GSM, TRQ, TRX
6 months ago - InvestorPlace

BEDMINSTER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the appointment of Natasha Giordano to its Board of Directors as an independe...

7 months ago - GlobeNewsWire

Topline data expected first quarter 2021 Topline data expected first quarter 2021

8 months ago - GlobeNewsWire

BEDMINSTER, N.J., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a...

8 months ago - GlobeNewsWire

Data published in Antimicrobial Agents and Chemotherapy demonstrate MAT2203 (oral amphotericin B) is well tolerated without the side effects commonly seen with IV amphotericin B Data published in Antimi...

8 months ago - GlobeNewsWire

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020.

8 months ago - Zacks Investment Research

On Monday, August 10, Matinas BioPharma Hldgs (AMEX: MTNB) will release its latest earnings report.

9 months ago - Benzinga

BEDMINSTER, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participa...

9 months ago - GlobeNewsWire

Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

9 months ago - Zacks Investment Research

BEDMINSTER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today anno...

9 months ago - GlobeNewsWire

Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

-   Topline data from ENHANCE-IT study of MAT9001 vs. Vascepa® expected in Q1 2021   - 

10 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor of Matinas BioPharma

11 months ago - Zacks Investment Research

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Matinas Biopharma Holdings Inc (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the...

11 months ago - Zacks Investment Research

BEDMINSTER, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United States Distr...

1 year ago - GlobeNewsWire

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of -33.33% and -100.00%, respectively, for the quarter ended December 2019.

1 year ago - Zacks Investment Research

Initiated ENHANCE-IT study of MAT9001 against Vascepa®. Topline data expected Q4 2020

1 year ago - GlobeNewsWire

– Topline data expected Q4 2020 –

1 year ago - GlobeNewsWire

President of American Board of Clinical Lipidology and nationally recognized expert in cardiovascular disease prevention and the diagnosis and treatment of cholesterol and hypertensive disorders Presid...

1 year ago - GlobeNewsWire

– Part 2 efficacy portion of EnACT expected to commence Q1 2020 –

1 year ago - GlobeNewsWire

While some argue you get what you pay for, others say that stocks trading at low levels can represent compelling opportunities.

Other stocks mentioned: DRRX, NOG, TAST, VBIV
1 year ago - InvestorPlace

Prospects Appear Bright for Small Drug Industry in 2020

Other stocks mentioned: AMRX, COLL, KALV
1 year ago - Zacks Investment Research

BEDMINSTER, N.J., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today anno...

1 year ago - GlobeNewsWire

The company announced the pricing of a public stock offering.

1 year ago - The Motley Fool

BEDMINSTER, N.J., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today anno...

1 year ago - GlobeNewsWire

BEDMINSTER, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today anno...

1 year ago - GlobeNewsWire

The small-cap pharma sank on an update from its top competitor.

1 year ago - The Motley Fool

Matinas And Amarin, And Other News And Issues: The Good, Bad, And Ugly Of Biopharma

Other stocks mentioned: AMRN
1 year ago - Seeking Alpha

About MTNB

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic ... [Read more...]

Industry
Biotechnology
Founded
2013
CEO
Jerome Jabbour
Employees
20
Stock Exchange
NYSEAMERICAN
Ticker Symbol
MTNB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for MTNB stock is "Buy." The 12-month stock price forecast is 3.08, which is an increase of 289.58% from the latest price.

Price Target
$3.08
(289.58% upside)
Analyst Consensus: Buy